TSHA Q1 2022 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$50M

Net Income

-$50M

EPS (Diluted)

$-1.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$52M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$166M

Total Liabilities

$115M

Stockholders' Equity

$51M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$50M	-$32M	-54.7%
Net Income	-$50M	-$32M	-57.1%